Global Chronic Pain Programs Market By Product (Drugs and Devices), By Indication (Cancer Pain, Neuropathic Pain, Chronic Back Pain, Arthritic Pain, Post-Operative Pain, and Other Indications), By End-user (Hospitals, Clinics, Nursing Homes, Research Organizations, and Other End-Users) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

Chronic Pain Programs Market size is expected to be worth around USD 96.17 Bn by 2032 from USD 52.7 Bn in 2022, growing at a CAGR of 6.2% during the forecast period from 2023 to 2032.

Request Covid - 19 Impact

Pain that continues for 3 months or longer than expected is termed chronic pain. Chronic pain arises from various causes including surgery or as a result of another ailment or accident. Patients with chronic pain syndrome undergo negative effects on both physical and emotional well-being. Chronic discomfort hampers day-to-day activities. It may cause pain to worsen as it can cause depression, insomnia, and anxiety. Key factors driving chronic pain market growth are the rising prevalence of chronic medical conditions, rising demand for over-the-counter medicines, growing use of opioids to treat neuropathic pain, and the cohesive network of retail pharmacies.

Market Scope:

Product Analysis

Based on product, the market for chronic pain programs is segmented into drugs, & devices. Drugs segment dominates the market for Chronic Pain Programs. This is primarily due to the rising prevalence of different types of chronic pain, like severe headaches, lower back pain, migraine pain, and facial pain. Also, increasing geriatric population globally, a sedentary lifestyle, and an increase in surgical procedures, the market is anticipated to grow during the forecast period.

Indication Analysis

Based on indication the market for chronic pain programs is segmented into cancer pain, neuropathic pain, chronic back pain, arthritic pain, post-operative pain, and other indications. The cancer pain category is the fastest-growing category during the forecast period. As per The National Cancer Institute (NCI), cancer is one of the leading causes of death globally. An increasing number of cancer survivors is surging the market growth, as the disease causes long-lasting and intense pain.

End-User Analysis

Based on end-user, the chronic pain program market is segmented into Hospitals, Clinics, Nursing Homes, Research Organizations, and Other End-Users. The hospital category dominates the chronic pain program market during the forecast period. Chronic pain programs are frequently carried out in Smart hospitals, especially for post-surgical pain, where monitoring costs and treatment for adverse effects raise demand for pain treatment drugs and devices.

Key Market Segments:

Based on Product

• Drugs
• Devices

Based on Indication

• Cancer Pain
• Neuropathic Pain
• Chronic Back Pain
• Arthritic Pain
• Post-Operative Pain
• Other Indications

Based on End-user

• Hospitals
• Clinics
• Nursing Homes
• Research Organizations
• Other End-Users

Market Dynamics:

Drivers

An increasing number of surgical procedures performed

The rise in the number of surgical procedures performed globally is a key factor driving the growth of the chronic pain program market. The increase in the prevalence of chronic conditions, like cancer and neurological disorders, leads to the growing demand for surgical interventions, that in turn has fostered the need for pain management devices. Also, technological advancements and the introduction of minimally invasive procedures fuel the market for chronic pain program market. Other factors influencing the market growth are increasing healthcare awareness, early diagnosis and treatment of diseases, an increase in the availability of healthcare services, and rising government initiatives for healthcare promotion.

Restraints

Use of medications as the first line of treatment for pain management

Many potential side effects associated with pain medications is the restraint of using pain medications as the first line of treatment for pain management. Some of the side effects are dizziness, drowsiness, constipation, and nausea. Few pain medications can be addictive leading to further issues. This is where pain medications play a key role. These devices facilitate a range of treatments, from electrotherapy to ultrasound, that can help in pain reduction without medications. These devices can be used in combination with other treatments like physical therapy, or standalone treatment. By exploring other forms of pain management, physicians and patients can reduce the risk of unwanted side effects and support effective pain management.

Opportunity

Excess Growth in Emerging Countries

An increase in awareness of benefits associated with chronic pain programs and increasing disposable incomes provides opportunities for market growth of chronic pain programs. As the demand for the product grows constantly, manufacturers offer improved products and services at competitive prices, which further drives the growth of the global chronic pain program market. Government initiatives in increasing healthcare access and affordability fuel market growth. Technological advancements also contribute to market expansion.

Trends

Modern pain management techniques boost the market growth. Key players consistently invest in the innovation of technological solutions for chronic pain programs. Innovation in wearable technologies is one of the most significant developments in the chronic pain program market. Increase in social insurance benefits that help individuals in monitoring pain-related diseases by government organizations in chronic pain reduction. The need for opioids as painkillers are increasing in low-income regions due to various government programs to facilitate palliative care for an individual with crippling cancer pain. Currently, the product lines focus on treating sickness rather than emphasizing its symptoms. Pharmaceutical companies are opting for chemical-based treatments rather than those based on biological products. Innovation of new, potent painkillers is supported by administrative reform.

COVID-19 Impact Analysis

The COVID-19 outbreak affected millions of individuals globally. COVID-19 has an economic impact and implications on many sectors including the medical industry. The lockdown harmed patients who relied on exercise programs or physiotherapy as a pain management regimen. Also, many elective procedures and delay in-person patient visits increase the need for residential pain treatment. Increasing cancer cases fuel the market growth during the forecast period.

Regional Analysis

North American region dominates the chronic pain program market due to rising denials in health reimbursement and an increasing number of startups facilitating healthcare software solutions. The global chronic pain program is expected to expand in Europe, and Asia Pacific during the forecast period due to improving health infrastructure and the rapid incorporation of technology by various hospitals and specialty clinics.

Key Regions

North America

• The US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

Emerging key players are focused on a variety of strategic policies to develop their respective businesses in foreign markets. Several chronic pain program market companies are concentrating on expanding their existing operations and R&D facilities. Furthermore, businesses in the chronic pain program market are developing new products and portfolio expansion strategies through investments and mergers, and acquisitions. In addition, several key players are now focusing on different marketing strategies such as spreading awareness about natural ingredients, which is boosting the target products' growth.

Recent Developments:

• In October 2022: Manufacturer and seller of pain relief creams, ultrasound and electromedical contact media, and institutional cleaners and disinfectants Parker Laboratories Inc., expand its analgesics line. Helix CBD Therapy, CBD clinical cream, and Tri-active therapy cream have been added to the HelixTM line.
• September 2022: Compass Group Equity Partners, a St. Louis-based private equity firm, announced a strategic partnership with Mays & Schnapp Neurospine and Pain ("Mays & Schnapp"), a Memphis-based interventional pain management practice serving patients in Tennessee and Mississippi.

Market Key Players

With the presence of many local and regional players, the market for companion diagnostics is fragmented. Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks. To stay on top of the market, companies have gained various expansion strategies such as partnerships and product launches.

The following are some of the major players in the Global Chronic Pain Program Market industry:

• Eli Lilly and Company
• GlaxoSmithKline plc
• Pfizer Inc.
• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Novartis AG
• Johnson & Johnson
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Becton, Dickinson and Company
• Sanofi S.A
• Other Key Players